In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found that a new imaging oral agent, also known as a “contrast agent,” helps radiologists better see bowel structures and disease in CT imaging when compared with the current oral contrast agents.